Literature DB >> 23993281

Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010.

Louisa Degenhardt1, Harvey A Whiteford, Alize J Ferrari, Amanda J Baxter, Fiona J Charlson, Wayne D Hall, Greg Freedman, Roy Burstein, Nicole Johns, Rebecca E Engell, Abraham Flaxman, Christopher J L Murray, Theo Vos.   

Abstract

BACKGROUND: No systematic attempts have been made to estimate the global and regional prevalence of amphetamine, cannabis, cocaine, and opioid dependence, and quantify their burden. We aimed to assess the prevalence and burden of drug dependence, as measured in years of life lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs).
METHODS: We conducted systematic reviews of the epidemiology of drug dependence, and analysed results with Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) Bayesian meta-regression technique (DisMod-MR) to estimate population-level prevalence of dependence and use. GBD 2010 calculated new disability weights by use of representative community surveys and an internet-based survey. We combined estimates of dependence with disability weights to calculate prevalent YLDs, YLLs, and DALYs, and estimated YLDs, YLLs, and DALYs attributable to drug use as a risk factor for other health outcomes.
FINDINGS: Illicit drug dependence directly accounted for 20·0 million DALYs (95% UI 15·3-25·4 million) in 2010, accounting for 0·8% (0·6-1·0) of global all-cause DALYs. Worldwide, more people were dependent on opioids and amphetamines than other drugs. Opioid dependence was the largest contributor to the direct burden of DALYs (9·2 million, 95% UI 7·1-11·4). The proportion of all-cause DALYs attributed to drug dependence was 20 times higher in some regions than others, with an increased proportion of burden in countries with the highest incomes. Injecting drug use as a risk factor for HIV accounted for 2·1 million DALYs (95% UI 1·1-3·6 million) and as a risk factor for hepatitis C accounted for 502,000 DALYs (286,000-891,000). Suicide as a risk of amphetamine dependence accounted for 854,000 DALYs (291,000-1,791,000), as a risk of opioid dependence for 671,000 DALYs (329,000-1,730,000), and as a risk of cocaine dependence for 324,000 DALYs (109,000-682,000). Countries with the highest rate of burden (>650 DALYs per 100,000 population) included the USA, UK, Russia, and Australia.
INTERPRETATION: Illicit drug use is an important contributor to the global burden of disease. Efficient strategies to reduce disease burden of opioid dependence and injecting drug use, such as delivery of opioid substitution treatment and needle and syringe programmes, are needed to reduce this burden at a population scale. FUNDING: Australian National Health and Medical Research Council, Australian Government Department of Health and Ageing, Bill & Melinda Gates Foundation.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23993281     DOI: 10.1016/S0140-6736(13)61530-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  262 in total

1.  Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice.

Authors:  Derek Vang; Jinny A Paul; Julia Nguyen; Huy Tran; Lucile Vincent; Dennis Yasuda; Nurulain T Zaveri; Kalpna Gupta
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

2.  Estimation of the Number of People With Opioid Addiction in Germany.

Authors:  Ludwig Kraus; Nicki-Nils Seitz; Bernd Schulte; Peter Cremer-Schaeffer; Barbara Braun; Uwe Verthein; Tim Pfeiffer-Gerschel
Journal:  Dtsch Arztebl Int       Date:  2019-03-01       Impact factor: 5.594

3.  Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances.

Authors:  Denise B Kandel; Mei-Chen Hu; Pamela Griesler; Melanie Wall
Journal:  Drug Alcohol Depend       Date:  2017-07-04       Impact factor: 4.492

4.  Core addiction medicine competencies for doctors: An international consultation on training.

Authors:  Astri Parawita Ayu; Nady El-Guebaly; Arnt Schellekens; Cor De Jong; Gabrielle Welle-Strand; William Small; Evan Wood; Walter Cullen; Jan Klimas
Journal:  Subst Abus       Date:  2017-07-18       Impact factor: 3.716

5.  Synaptic Plasticity in the Bed Nucleus of the Stria Terminalis: Underlying Mechanisms and Potential Ramifications for Reinstatement of Drug- and Alcohol-Seeking Behaviors.

Authors:  Nicholas A Harris; Danny G Winder
Journal:  ACS Chem Neurosci       Date:  2018-06-13       Impact factor: 4.418

6.  Evaluating the care cascade after antiretroviral therapy initiation in Latin America.

Authors:  Marcelo J Wolff; Claudia P Cortes; Fernando A Mejìa; Denis Padgett; Pablo Belaunzarán-Zamudio; Beatriz Grinsztejn; Mark J Giganti; Catherine C McGowan; Peter F Rebeiro
Journal:  Int J STD AIDS       Date:  2017-06-15       Impact factor: 1.359

Review 7.  Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review.

Authors:  Mishka Terplan; Dennis J Hand; Melissa Hutchinson; Elizabeth Salisbury-Afshar; Sarah H Heil
Journal:  Prev Med       Date:  2015-04-18       Impact factor: 4.018

8.  The complex interplay of social networks, geography and HIV risk among Malaysian Drug Injectors: Results from respondent-driven sampling.

Authors:  Alexei Zelenev; Elisa Long; Alexander R Bazazi; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2016-09-15

Review 9.  Annual research review: Optimal outcomes of child and adolescent mental illness.

Authors:  E Jane Costello; Barbara Maughan
Journal:  J Child Psychol Psychiatry       Date:  2014-12-12       Impact factor: 8.982

10.  The causal effect of opioid substitution treatment on HAART medication refill adherence.

Authors:  Bohdan Nosyk; Jeong E Min; Guillaume Colley; Viviane D Lima; Benita Yip; M-J S Milloy; Evan Wood; Julio S G Montaner
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.